Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773622 | 0.80 | CYP4F2 (0.38) | CYP4F2CYP4A11FAAHCNR1CNR2 | |
| SCHEMBL15633296 | 0.79 | CYP4F2 (0.40) | CYP4F2CYP4A11FAAHCNR1CNR2 | |
| SCHEMBL15633630 | 0.78 | CYP4F2 (0.38) | CYP4F2CYP4A11FAAHCNR1CNR2 | |
| SCHEMBL24977890 | 0.76 | CYP4F2 (0.35) | GRM5SLC16A3SLC16A1MCTS1CYP4F2 | |
| SCHEMBL24977875 | 0.71 | CYP4F2 (0.36) | GRM5SLC16A3SLC16A1MCTS1CYP4F2 | |
| SCHEMBL15633360 | 0.70 | MAPT (0.34) | GRM5GRM1SLC16A3SLC16A1MCTS1 | |
| SCHEMBL24977637 | 0.66 | TDP1 (0.38) | CYP4F2CYP4A11FAAHALDH1A1 | |
| SCHEMBL4140061 | 0.66 | LMNA (0.48) | HPGD | |
| SCHEMBL10175323 | 0.65 | MGLL (0.41) | — | |
| SCHEMBL1117827 | 0.65 | MGLL (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3656384-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3785714-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3125894-B1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3656384-A1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME CORP. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3295942-B1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10189831-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3295942-A1 | COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV | MERCK SHARP & DOHME CORP. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170349585-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349585-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-07 | — | — | US | disclosed |
| EP-3125894-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-9469634-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469634-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2015153304-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153304-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | WO | disclosed |
| EP-2903977-A1 | 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014058747-A1 | 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20140100231-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145255-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | GRM5 3616/4885DRD1 2446/4885GRM1 3073/4885 |
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | TYMP, RNGTT, REV1 | GRM5 4307/4885DRD1 2379/4885GRM1 3398/4885 |
| US-20140100231-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | GRM5 3616/4885DRD1 2446/4885GRM1 3073/4885 |
| US-20170349585-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR2E, RTF1 | GRM5 3616/4885DRD1 2446/4885GRM1 3073/4885 |
| US-10189831-B2 | Non-nucleoside reverse transcriptase inhibitors | POLRMT, POLR2E, RTF1 | GRM5 3616/4885DRD1 2446/4885GRM1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.